BriaCell Therapeutics Common Stock

BriaCell Therapeutics (BCTX) currently reports a common stock of $120M as of April 2026. That compares with $94M in the prior-year period — up 24.6% year over year. Use the charts on this page to explore BriaCell Therapeutics's common stock history and peer comparisons.

BriaCell Therapeutics's common stock increased from $94M to $120M — a 24.6% year-over-year increase (period ending April 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BriaCell Therapeutics reported $120M in common stock as of April 2026. That compares with $94M in the prior-year period — up 24.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $120M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BriaCell Therapeutics, and consider following BCTX for alerts when major investors trade the stock.

BriaCell Therapeutics is classified in the Healthcare sector. On common stock, it currently shows $120M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCTX with unrelated industries.